Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II
Iloprost treatment seems a safe and promising therapeutic option also in SONK with excellent subjective outcome and reduction of BME of 70% within 3 months after Iloprost infusion.
Authors
- Stefanie Donner (ORCID: https://orcid.org/0000-0001-8270-0462)
- Stephanie Kirschbaum (ORCID: https://orcid.org/0000-0001-8263-4354)
- Clemens Gwinner (ORCID: https://orcid.org/0000-0001-7489-245X)
- Carsten Perka (ORCID: https://orcid.org/0000-0002-0993-581X)
- Thula Walter (ORCID: https://orcid.org/0000-0002-2003-8351)
- Moses K. D. El Kayali (ORCID: https://orcid.org/0000-0002-0280-1819)
- Maurice Soujon
Institutions
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Archives of Orthopaedic and Trauma Surgery
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1007/s00402-025-06057-7
- Primary Topic
- Bone and Joint Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00